HLA-G Specific Antibodies And Uses Thereof

By developing specific antibodies that can bind HLA-G, inhibiting the binding of HLA-G to immune cell receptors, the problem of cancer cells evading the immune system has been solved, and the targeting ability of immune cells to cancer cells and patient survival rate has been significantly improved. .

CN119072495APending Publication Date: 2024-12-03HK INNO N CORP +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380030248.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-25
Filing Date
2023-03-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing cancer treatments are not effective after cancer cells metastasis, and cancer cells evade the immune system by expressing human leukocyte antigen-G (HLA-G), resulting in a reduced targeting ability of immune cells.

Method used

Developing HLA-G-specific antibodies that can bind HLA-G monomers and dimers to inhibit the binding of HLA-G to immune cell receptors, thereby enhancing the targeting ability of immune cells to cancer cells.

Benefits of technology

By inhibiting HLA-G function, the killing ability of immune cells to cancer cells is improved, the growth and metastasis of cancer cells is inhibited, and the survival rate of patients is significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072495A_ABST
    Figure CN119072495A_ABST
Patent Text Reader

Abstract

The present invention relates to an antibody that specifically binds to HLA-G, which binds to HLA-G monomers and polymers, thereby preventing binding of HLA-G to its receptor, thereby being effectively used in cancer treatment, and to the use thereof in cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an antibody specifically binding to human leukocyte antigen-G (HLA-G) and its use in cancer treatment. Background Art

[0002] Although cancer has been intensively studied over the past few decades, it remains a leading cause of death worldwide. Many cancer treatments have been developed, and methods such as surgery, chemotherapy, and radiotherapy are still used today. However, most of these existing cancer treatments are only effective in the early stages when the cancer has not yet metastasized, and there is a problem that when metastasis has already occurred, there is a high probability of recurrence even after surgery. Therefore, in order to treat cancer more effectively, research on immunotherapy that utilizes immune response has been ongoing.

[0003] Immunotherapy is a treatment method that prevents cancer cells from evading the body's immune system, thereby allowing immune cells to better recognize and attack cancer cells. Specifically, immunotherapy can induce cancer cell death through nonspecific immune cell activation or induce an immune response against tumors in cancer patients' immune cells using tumor-specific antigens.

[0004] Meanwhile, human major histocompatibility complex class I G, also known as human leukocyte antigen-G (HLA-G), is an immune checkpoint that inhibits the activation and division of T cells, natural killer (NK) cells, and cytotoxic T cells. Known immune cell receptors for HLA-G include Ig-like transcript 2 (ILT2), ILT4, and killer cell immunoglobulin-like receptor two Ig domains and long cytoplasmic tail 4 (KIR2DL4), and all of these receptors have an immunoreceptor tyrosine-based inhibitory (ITIM) motif. When HLA-G binds to the receptor, the signaling pathway that inhibits immune cells is activated by this motif.

[0005] Although the expression of HLA-G is limited to normal cells, it has been reported that HLA-G is expressed in many types of cancer cells (Lin A, Yan WH. Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy. Mol Med. 21 (1), 782-791 (2015)). In addition, it has been reported that the expression level of HLA-G in cancer cells of many cancer patients is related to the stage of cancer, and it has also been reported that patients expressing HLA-G have a lower survival rate (Ye, Sr., Yang, H., Li, K. et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 20, 375-383 (2007)). Summary of the invention

[0006] Technical issues

[0007] Under the above circumstances, the present inventors have attempted to develop human leukocyte antigen-G (HLA-G) specific antibodies to increase the targeting ability of immune cells to cancer cells by inhibiting the function of HLA-G. Therefore, the present inventors have developed an HLA-G specific antibody capable of binding to HLA-G monomers and dimers, thereby completing the present invention.

[0008] Therefore, one object of the present invention is to provide an HLA-G specific antibody or an antigen-binding fragment thereof.

[0009] In addition, another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, which provides an HLA-G specific antibody or an antigen-binding fragment thereof as an active ingredient.

[0010] Technical Solution

[0011] To achieve the above object, one aspect of the present invention provides an anti-HLA-G antibody or an antigen-binding fragment thereof, wherein the anti-HLA-G antibody or the antigen-binding fragment thereof comprises:

[0012] (a) a heavy chain complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and

[0013] a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:5, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:6, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:7;

[0014] (b) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and

[0015] a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15;

[0016] (c) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 19; and

[0017] a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 22, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 23; or

[0018] (d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and

[0019] A light chain CDR1 comprising the amino acid sequence of SEQ ID NO:29, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:31.

[0020] In the present invention, the anti-HLA-G antibody or antigen-binding fragment thereof may comprise the following sequence:

[0021] (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO: 4, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO: 8;

[0022] (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO: 16;

[0023] (c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO: 20 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO: 24; or

[0024] (d) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:28 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO:28, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:32 or an amino acid sequence having 80% or greater homology to the amino acid sequence of SEQ ID NO:32.

[0025] More specifically, in one embodiment of the present invention, the anti-HLA-G antibody or antigen-binding fragment thereof may comprise the following sequence:

[0026] (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8;

[0027] (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16;

[0028] (c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24; or

[0029] (d) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:28 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:32.

[0030] As used herein, the term "antibody" refers to a protein molecule used as a receptor for specific antigen recognition, including immunoglobulin molecules that are immunologically reactive to specific antigens. Antibodies include monoclonal antibodies, polyclonal antibodies, mixtures of monoclonal and / or polyclonal antibodies, full-length antibodies, and antibody fragments. Full-length antibodies or complete antibodies are used interchangeably and refer to antibodies having a structure substantially similar to a natural antibody structure or having a heavy chain containing a crystallizable fragment (Fc) region as defined herein.

[0031] Furthermore, antibodies may include bivalent or bispecific molecules (eg, bispecific antibodies). Additionally, depending on the source of the sequence, the antibody may be a human antibody, a humanized antibody, or a chimeric antibody.

[0032] As used herein, the term "monoclonal antibody" refers to an antibody molecule composed of a single molecule obtained from a substantially identical antibody population, and such monoclonal antibodies show a single binding and affinity to a specific epitope, which is different from polyclonal antibodies that can bind to multiple epitopes. As used herein, the term "full-length antibody" has a structure comprising two full-length light chains and two full-length heavy chains, and each light chain is connected to the heavy chain by a disulfide bond. The heavy chain constant region has gamma (γ), muon (μ), alpha (α), delta (δ) and epsilon (ε) types, and has gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1) and alpha 2 (α2) as subclasses. The light chain constant region has Kapa (κ) and lambda (λ) types. IgG has subtypes, including IgG1, IgG2, IgG3 and IgG4.

[0033] As used herein, the term "heavy chain" may include a full-length heavy chain comprising a variable region VH (comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen) and three constant regions CH1, CH2 and CH3 and fragments thereof. In addition, as used herein, the term "light chain" may include a full-length light chain comprising a variable region VL (comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen) and a constant region CL and fragments thereof.

[0034] As used herein, the term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is derived from a specific source or species, while the rest of the heavy chain and / or light chain is derived from a different source or species. For example, there is a chimeric antibody formed by recombining the variable region of a mouse antibody with the constant region of a human antibody, and it is an antibody with greatly improved immune response compared to a mouse antibody.

[0035] As used herein, the term "humanized antibody" refers to an antibody formed by modifying the protein sequence of an antibody derived from a non-human species to make it similar to an antibody naturally produced in the human body. For example, a humanized variable region can be produced by recombining a CDR derived from a mouse with a framework region (FR) derived from a human antibody, and recombining it with a preferred human antibody constant region to produce a humanized antibody. However, when only CDR transplantation is performed, the affinity of the humanized antibody is reduced, and therefore, by replacing several important FR amino acid residues that are believed to affect the three-dimensional structure of CDR with FR amino acid residues of mouse antibodies, the affinity can be increased to the same level as the original mouse antibody.

[0036] In addition, the present invention provides an antigen-binding fragment of an anti-HLA-G antibody. The antigen-binding fragment may be selected from the group consisting of an antigen-binding fragment (Fab), Fab', F(ab')2, a variable fragment (Fv), a disulfide-stabilized Fv fragment (dsFv), a single-chain Fv (scFv), a diabody, a triabody, and a tetrabody.

[0037] As used herein, the terms "fragment", "antibody fragment", "antigen binding fragment" or "antigen binding domain" are used interchangeably and refer to any fragment of an antibody of the present invention that has the antigen binding function of an antibody. Exemplary antigen binding fragments include Fab, Fab', F(ab')2 and Fv, but are not limited thereto.

[0038] Fab has one antigen binding site, and its structure has the variable regions of light chain and heavy chain, the constant region of light chain and the first constant region (CH1 domain) of heavy chain. Fab' is different from Fab in that it has a hinge region including one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. When the cysteine ​​residues in the hinge region of Fab' form a disulfide bond, a F(ab')2 antibody is produced. Fv is the smallest antibody fragment having only the variable region of the heavy chain and the variable region of the light chain, and the recombinant technology for producing Fv fragments is disclosed in PCT International Patent Publications WO 88 / 10649, WO 88 / 106630, WO 88 / 07085, WO88 / 07086 and WO 88 / 09344, etc. Double-chain Fv has a heavy chain variable region and a light chain variable region connected by a non-covalent bond, and a single-chain Fv generally has a heavy chain variable region and a light chain variable region connected by a covalent bond or directly connected at the C-terminus via a peptide linker, so that a dimer structure similar to a double-chain Fv can be formed. These antibody fragments can be obtained using proteases (for example, Fab can be obtained by restrictive digestion of the whole antibody with papain, and F(ab')2 fragments can be obtained by digestion with pepsin), and can preferably be produced by genetic recombination technology.

[0039] Diabodies are small bivalent antibodies consisting of two heavy chain variable domains and two light chain variable domains, each light chain variable domain is connected to a heavy chain variable domain by a short linker. When the light chain variable domains are connected to the heavy chain variable domains by a much shorter linker, tria or tetrabodies can be formed.

[0040] In addition, the antibodies or antigen-binding fragments thereof of the present invention may include not only the sequences of the anti-HLA-G antibodies described herein, but also their biological equivalents (to the extent that they can exhibit binding ability to HLA-G). For example, the amino acid sequence of the antibody may be further altered to further improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletions, insertions and / or substitutions of residues in the amino acid sequence of the antibody. Such amino acid mutations are based on the relative similarity of the amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, etc. By analyzing the size, shape and type of the amino acid side chain substituents, it can be seen that arginine, lysine and histidine are all positively charged residues; alanine, glycine and serine have similar sizes; and phenylalanine, tryptophan and tyrosine have similar shapes. Therefore, based on this point, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine can be regarded as biological functional equivalents.

[0041] Another aspect of the present invention is an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof. The antibody and antigen-binding fragment thereof are as described above.

[0042] As used herein, the term "nucleic acid" has a comprehensive meaning, including DNA (genomic DNA (gDNA) and complementary DNA (cDNA)) and RNA molecules, and nucleotides as the basic units of nucleic acid molecules, including not only natural nucleotides, but also analogs in which the sugar or base moiety is modified (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews (1990) 90: 543-584). The sequences of the nucleic acid molecules encoding the heavy and light chain variable regions of the present invention can be modified, and the modifications include the addition, deletion, or non-conservative or conservative substitution of nucleotides.

[0043] In the present invention, the isolated nucleic acid may comprise the following sequence:

[0044] (a) the nucleotide sequence of SEQ ID NO:37 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:37 and the nucleotide sequence of SEQ ID NO:38 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:38;

[0045] (b) the nucleotide sequence of SEQ ID NO:39 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:39 and the nucleotide sequence of SEQ ID NO:40 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:40;

[0046] (c) the nucleotide sequence of SEQ ID NO:41 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:41 and the nucleotide sequence of SEQ ID NO:42 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:42; or

[0047] (d) the nucleotide sequence of SEQ ID NO:43 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:43 and the nucleotide sequence of SEQ ID NO:44 or a nucleotide sequence having 80% or greater homology to the nucleotide sequence of SEQ ID NO:44.

[0048] More specifically, in one embodiment of the present invention, the isolated nucleic acid may comprise the following sequence:

[0049] (a) the nucleotide sequence of SEQ ID NO: 37 and the nucleotide sequence of SEQ ID NO: 38;

[0050] (b) the nucleotide sequence of SEQ ID NO:39 and the nucleotide sequence of SEQ ID NO:40;

[0051] (c) the nucleotide sequence of SEQ ID NO:41 and the nucleotide sequence of SEQ ID NO:42; or

[0052] (d) The nucleotide sequence of SEQ ID NO:43 and the nucleotide sequence of SEQ ID NO:44.

[0053] Still another aspect of the present invention is a recombinant vector comprising a nucleic acid molecule.

[0054] As used herein, the term "vector" refers to a tool for expressing a target gene in a host cell, including plasmid vectors; cosmid vectors; and viral vectors, such as phage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors, and may preferably be a plasmid vector, but is not limited thereto.

[0055] According to one embodiment of the present invention, the recombinant vector comprising a nucleic acid molecule of the present invention may comprise a nucleic acid molecule encoding a sequence comprising the following CDRs or comprising a heavy chain and / or light chain variable region comprising the following CDRs:

[0056] (a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and

[0057] a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:5, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:6, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:7;

[0058] (b) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and

[0059] a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15;

[0060] (c) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 19; and

[0061] a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 22, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 23; or

[0062] (d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and

[0063] A light chain CDR1 comprising the amino acid sequence of SEQ ID NO:29, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:31.

[0064] In the vector of the present invention, the nucleic acid molecule encoding the light chain variable region and the nucleic acid molecule encoding the heavy chain variable region may be operably linked to a promoter.

[0065] As used herein, the term "operably linked" refers to a functional connection between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence, or a transcription factor binding site array) and another nucleic acid sequence, whereby the regulatory sequence regulates the transcription and / or translation of the other nucleic acid sequence.

[0066] The recombinant vector system of the present invention can be constructed by various methods known in the art, and the specific methods are disclosed in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001), which is incorporated herein by reference.

[0067] The vector of the present invention can generally be constructed as a vector for cloning or a vector for expression. The recombinant vector of the present invention is preferably an expression vector. In addition, the vector of the present invention can be constructed using prokaryotic cells or eukaryotic cells as hosts.

[0068] For example, when the vector of the present invention is an expression vector and a prokaryotic cell is used as a host, the vector generally comprises a strong promoter capable of promoting transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, T7 promoter, etc.), a ribosome binding site for initiating translation, and a transcription / translation termination sequence. When Escherichia coli (E. coli) (e.g., HB101, BL21, DH5α, etc.) is used as a host cell, the promoter and operator region of the E. coli tryptophan biosynthetic pathway (Yanofsky, C., J. Bacteriol., (1984) 158: 1018-1024) and the leftward promoter of bacteriophage λ (pLλ promoter, Herskowitz, I. and Hagen, D., Ann. Rev. Genet., (1980) 14: 399-445) can be used as a regulatory region. When a Bacillus bacterium is used as a host cell, the promoter of the toxin protein gene of Bacillus thuringiensis (Appl. Environ. Microbiol. (1998) 64: 3932-3938; Mol. Gen. Genet. (1996) 250: 734-741) or any promoter that can be expressed in a Bacillus bacterium can be used as a regulatory region.

[0069] At the same time, the recombinant vector of the present invention can be produced by manipulating plasmids commonly used in the art (for example, pCL, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series and pUC19, etc.), bacteriophages (for example, λgt4·λB, λ-Charon, λΔz1 and M13, etc.) or viruses (for example, SV40, etc.).

[0070] Meanwhile, when the vector of the present invention is an expression vector and a eukaryotic cell is used as a host, a promoter derived from the genome of a mammalian cell (e.g., a metallothionein promoter, a β-actin promoter, a human hemoglobin promoter, and a human muscle creatine promoter) or a promoter derived from a mammalian virus (e.g., an adenovirus late promoter, a vaccinia virus 7.5K promoter, an SV40 promoter, a cytomegalovirus (CMV) promoter, a HSV tk promoter, a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus long terminal repeat (HIV LTR) promoter, a Moloney virus promoter, an Epstein-Barr virus (EBV) promoter, and a Rous sarcoma virus (RSV) promoter) can be used, and it generally has a polyadenylation sequence as a transcription termination sequence. Specifically, the recombinant vector of the present invention may include a CMV promoter.

[0071] The recombinant vector of the present invention can be fused with another sequence to facilitate the purification of the antibody expressed therefrom. Fusion sequences include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and hexahistidine (6x His; Quiagen, USA). In addition, since the protein expressed by the vector of the present invention is an antibody, the expressed antibody can be easily purified by a protein A column or the like without the need for additional sequences for purification.

[0072] At the same time, the recombinant vector of the present invention may contain antibiotic resistance genes commonly used in the art as selection markers, and may contain resistance genes for example to ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline. According to one embodiment of the present invention, the anti-HLA-G expression vector may contain an ampicillin resistance gene.

[0073] The carrier of the expression antibody of the present invention can be a carrier system in which light chain and heavy chain are expressed simultaneously in a single carrier, or a system in which light chain and heavy chain are expressed in a separate carrier respectively. In the latter case, two carriers are introduced into the host cell by co-transformation and targeted transformation. Co-transformation is to introduce the corresponding vector DNA encoding light chain and heavy chain into the host cell simultaneously, and then select the method for expressing the cell of both light chain and heavy chain. Targeted transformation is to select the cell transformed with the carrier comprising light chain (or heavy chain), and the selected cell expressing light chain is transformed with the carrier comprising heavy chain (or light chain) again to finally select the method for expressing the cell of both light chain and heavy chain.

[0074] The nucleic acid encoding the heavy chain and light chain of the antibody of the present invention is inserted into the expression vector encoding the heavy chain constant region and light chain constant region of human IgG1, IgG2, IgG4. The light chain and heavy chain can be cloned in the same or different expression vectors. The DNA sequence encoding the immunoglobulin chain can be operably connected to the control sequence in the expression vector to ensure the expression of the immunoglobulin polypeptide. Such control sequences include signal sequences, promoters, enhancers and transcription termination sequences. The expression vector is an integral part of the host chromosome DNA or episome, and can be replicated in the host organism.

[0075] When the heavy and light chains of an antibody are cloned into separate vectors, the expression vectors encoding the heavy and light chains can be co-transfected into a single host cell to express both chains, and the chains can be assembled in vivo or in vitro to form a complete antibody.

[0076] Alternatively, the expression vector encoding the heavy chain and the expression vector encoding the light chain can be introduced into different host cells, to express the heavy chain and the light chain respectively, then the chain can be purified and assembled in vitro to form a complete antibody. Antibodies as described herein or fragments thereof can be produced in prokaryotic or eukaryotic expression systems such as bacteria, yeast, filamentous fungi, insects and mammalian cells. Although the recombinant antibodies of the present invention do not necessarily need glycosylation or are expressed in eukaryotic cells, they are usually preferably expressed in mammalian cells. Examples of available mammalian host cell lines are human embryonic kidney cell lines (HEK 293 cells), baby hamster kidney cells (BHK cells), Chinese hamster ovary cells / - or + dihydrofolate reductase (DHFR) (CHO, CHO-S, CHO-DG44, Flp-in CHO cells), African green monkey kidney cells (VERO cells) and human hepatocytes (Hep G2 cells).

[0077] Expression vectors for these cells may contain expression control sequences, such as replication origins, promoters and enhancers, and necessary processing information sites, such as ribosome binding sites, RNA splicing sites, polyadenylation sites and transcription terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, Simian virus 40 (SV40), adenovirus, bovine papilloma virus, cytomegalovirus, etc. The vector containing the plasmid sequence for producing antibodies can be transferred into host cells by well-known methods, which may vary depending on the type of host cell.

[0078] Yet another aspect of the present invention is a host cell comprising a recombinant vector. Preferably, the host cell of the present invention is a host cell transformed with a recombinant vector.

[0079] Host cells capable of stably and continuously cloning and expressing the vectors of the present invention may be any host cells known in the art and may include, for example, prokaryotic host cells such as Escherichia coli, Bacillus such as Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis, or Staphylococcus (e.g., Staphylococcus carnosus) strains, but are not limited thereto.

[0080] Suitable eukaryotic host cells transformed with the vector may be fungi such as Aspergillus species, yeasts such as Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces and Neurospora crassa, other lower eukaryotic cells, higher eukaryotic cells such as cells of insect origin, and cells derived from plants or mammals, but are not limited thereto.

[0081] Specifically, the host cell can be monkey kidney cell 7 (COS7), NS0 cell, SP2 / 0, CHO cell, W138, BHK cell, Mardin Darby dog ​​kidney (MDCK) cell, myeloma cell line, HuT 78 cell or 293 cell.

[0082] Mammalian host cell culture is preferred for the expression and production of anti-HLA-G antibodies or antigen-binding fragments thereof, as a variety of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art.

[0083] In the present invention, "transformation" and / or "transfection" into a host cell includes any method for introducing nucleic acid into an organism, cell, tissue or organ, and can be performed by selecting standard techniques suitable for host cells as known in the art. Such methods include electroporation, protoplast fusion, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, stirring with silicon carbide fibers, Agrobacterium (Agrobacterium)-mediated transformation, polyethylene glycol (PEG), dextran sulfate, liposomes (lipofectamine) and dryness / inhibition-mediated transformation methods, but are not limited thereto.

[0084] Yet another aspect of the present invention is a method for producing an anti-HLA-G antibody or an antigen-binding fragment thereof, the method comprising culturing the transformed host cell of the present invention. Preferably, the method for producing an anti-HLA-G antibody or an antigen-binding fragment thereof of the present invention may further comprise expressing the anti-HLA-G antibody or an antigen-binding fragment thereof in the cultured transformed host cell.

[0085] In the method for producing an antibody or its antigen-binding fragment, the culture of the transformed host cell can be carried out according to appropriate culture medium and culture conditions known in the art. Those skilled in the art can easily adjust and use such a culture process according to the selected strain. Various of these culture methods are disclosed in various documents (e.g., James M. Lee, Biochemical Engineering, Prentice-Hall International Editions, 138-176). Cell culture is divided into suspension culture and adherent culture according to the cell growth method, and is divided into batch culture, fed-batch culture and continuous culture according to the culture method. The culture medium used for cultivation needs to appropriately meet the needs of specific strains.

[0086] In animal cell culture, culture medium contains various carbon sources, nitrogen sources and trace element components. Examples of spendable carbon sources include carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch and cellulose, fats such as soybean oil, sunflower seed oil, castor oil and coconut oil, fatty acids such as palmitic acid, stearic acid and linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid, and these carbon sources can be used alone or in combination.

[0087] The nitrogen source that can be used for the present invention includes organic nitrogen sources such as peptone, yeast extract, meat juice, malt extract, corn steep liquor (CSL) and soybean meal, and inorganic nitrogen sources such as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, and these nitrogen sources can be used alone or in combination. The culture medium can contain potassium dihydrogen phosphate, dipotassium hydrogen phosphate and corresponding sodium salts as phosphorus sources. In addition, the culture medium can contain metal salts, such as magnesium sulfate or ferric sulfate. In addition, it can also contain amino acids, vitamins and suitable precursors.

[0088] During the culture, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid can be added to the culture in an appropriate manner to adjust the pH of the culture. In addition, during the culture, defoamers such as fatty acid polyglycol esters can be used to inhibit bubble formation. In addition, in order to maintain the aerobic conditions of the culture, oxygen or oxygen-containing gas (e.g., air) is injected into the culture. The temperature of the culture can generally be 20°C to 45°C, preferably 25°C to 40°C, but is not limited thereto.

[0089] The antibodies obtained by culturing transformed host cells can be used in an unpurified state, and can be further purified to high purity using various conventional methods such as dialysis, salt precipitation and chromatography. Among them, the method using chromatography is the most commonly used, and the type and order of the columns can be selected from ion exchange chromatography, size exclusion chromatography and affinity chromatography according to the characteristics of the antibody, the culturing method, etc.

[0090] The anti-HLA-G antibody according to the present invention is produced using the multimeric structure of HLA-G as an antigen, and is characterized in that it can bind to both HLA-G monomers and multimers. Since HLA-G is known to inhibit the activation of immune cells and is overexpressed in cancer cells, the inventors confirmed the anti-cancer ability of the anti-HLA-G antibody.

[0091] Therefore, it was confirmed that the anti-HLA-G antibody inhibits the binding of HLA-G to CD8a (Table 4). In addition, it was confirmed that when peripheral blood mononuclear cells (PBMC, effector cells) and target cells treated with anti-HLA-G antibodies were mixed with cancer cells and co-cultured, the cancer cells were killed ( Figure 3 ) and tumor growth was inhibited in tumor-induced mice (Table 6).

[0092] Therefore, another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, which comprises the antibody or antigen-binding fragment thereof of the present invention as an active ingredient.

[0093] In the present invention, the pharmaceutical composition can be used to treat cancers that overexpress HLA-G, but is not limited thereto. The cancer can be selected from the group consisting of pancreatic cancer, breast cancer, ovarian cancer, glioma, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, liver cancer, lung cancer, colon cancer, nasopharyngeal cancer, oral cancer, thyroid cancer, prostate cancer, kidney cancer, gallbladder cancer, bile duct cancer, blood cancer, melanoma, etc.

[0094] The blood cancer may be acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), multiple myeloma (MM), or lymphoma.

[0095] As used herein, the term "prevention" refers to any action to inhibit or delay the progression of a disease by administering the composition of the present invention, and "treatment" refers to inhibiting, alleviating or eliminating the development of a disease.

[0096] The pharmaceutical composition of the present invention may also include a pharmaceutically acceptable carrier, which is a carrier commonly used in preparation and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil, but is not limited thereto. In addition to the above ingredients, the composition for preventing or treating cancer of the present invention may also include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. Suitable pharmaceutically acceptable carriers and preparations are described in detail in the document [Remington's Pharmaceutical Sciences (19th edition, 1995)].

[0097] The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and intrarectal administration, etc. In the case of oral administration, since the protein or peptide is digested, the oral composition can be formulated to coat the active agent or protect it from decomposition in the stomach, and the composition of the present invention can be administered by any means that allows the active substance to move to the target cells.

[0098] The suitable dosage of the pharmaceutical composition of the present invention depends on factors such as formulation method, administration method, patient's age, weight, sex and pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity and changes, and a doctor of ordinary skill can easily determine the effective dosage for the desired treatment or prevention and prescribe. According to one embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention may be 0.1mg / kg to 100mg / kg, preferably 0.1mg / kg to 10mg / kg, and more preferably 0.1mg / kg to 2mg / kg. As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to treat, prevent and diagnose a disease.

[0099] The pharmaceutical composition of the present invention can be prepared in unit dosage form, or can be prepared by placing it in a multidose container, by using a pharmaceutically acceptable carrier and / or excipient according to the method that can be easily implemented by a technician in the field of the present invention. At this time, the preparation can be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or it can be in the form of an extract, powder, granule, tablet or capsule, and can also contain a dispersant and / or a stabilizer.

[0100] The compositions of the present invention may be administered as a sole therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.

[0101] The antibody or antigen-binding fragment thereof of the present invention can be used to treat cancer by administering it to a living body in the form of an antibody-therapeutic agent (functional molecule) and a bispecific antibody-therapeutic agent (functional molecule) conjugate. Various conditions suitable for and preferably used to target a drug to a specific target site have been reported in, for example, the literature [Trouet et al., Plenum Press, New York and London, (1982) 19-30].

[0102] The antibodies or antigen-binding fragments thereof of the present invention can be further combined or co-administered with functional molecules for the prevention, treatment and diagnosis of diseases associated with HLA-G overexpression. Functional molecules can include chemical substances, radionuclides, immunotherapeutic agents, cytokines, chemokines, toxins, biological agents and enzyme inhibitors.

[0103] Yet another aspect of the present invention provides a method for diagnosing, preventing or treating a disease associated with HLA-G overexpression (e.g., cancer), the method comprising administering the antibody or antigen-binding fragment thereof, or the pharmaceutical composition of the present invention to a subject, such as a human or non-human mammal, in a pharmaceutically effective amount. The present invention also provides a method for diagnosing a disease associated with HLA-G overexpression (e.g., cancer), the method comprising administering the antibody or antigen-binding fragment thereof of the present invention to a subject, such as a human or non-human mammal, in need thereof.

[0104] As used herein, the term "subject" refers to any animal that has developed or is likely to develop a disease associated with HLA-G overexpression, including humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quail, cats, dogs, mice, rats, rabbits, or guinea pigs.

[0105] At the same time, the present inventors confirmed the binding site of the antibody and HLA-G, and thus, confirmed that in the amino acid sequence of the antigen used for antibody screening (SEQ ID NO: 33), amino acids 339 to 344 (DYEATL), amino acids 390 to 402 (VVVPSGEEQRYTC) and amino acids 323 to 338 (QRADPPKTHVTHHPVF) are epitopes.

[0106] Therefore, yet another aspect of the present invention provides an HLA-G epitope consisting of a sequence selected from the group consisting of SEQ ID NOs: 34 to 36.

[0107] As used herein, the term "epitope" refers to a local site of an antigen to which an antibody or fragment thereof can specifically bind. An epitope is usually composed of surface groups of a molecule, such as amino acids or sugar side chains, and usually has specific three-dimensional structural characteristics and specific charge characteristics. The difference between a conformational epitope and a non-conformational epitope is that the binding to the conformational epitope is lost in the presence of a denaturing solvent, while the binding to the non-conformational epitope is not lost. An epitope may include amino acid residues that are directly involved in binding (also referred to as the immunodominant component of an epitope) and other amino acid residues that are not directly involved in binding, such as amino acid residues that are effectively blocked by a specific antigen-binding peptide (i.e., amino acid residues that are present in the footprint of a specific antigen-binding peptide).

[0108] The present invention also provides an antibody that specifically binds to an HLA-G epitope, and specific examples of the antibody are the same as those described above, but are not limited thereto.

[0109] Beneficial Effects

[0110] The anti-HLA-G antibody according to the present invention can bind to monomers and multimers of HLA-G, and thus can effectively block the binding of HLA-G to its receptor. BRIEF DESCRIPTION OF THE DRAWINGS

[0111] Figure 1 is a schematic diagram for producing b2m-HLA-G antigen according to one embodiment of the present invention.

[0112] Figure 2 The vector structure used to produce anti-HLA-G antibodies is shown.

[0113] Figure 3 The results show that HLA-G overexpressing target cells treated with an anti-HLA-G antibody were mixed with peripheral blood mononuclear cells (PBMCs), the mixed cells were co-cultured with SK-OV-3 cells or MDA-MB-231 cells, and the degree of cancer cell death was confirmed.

[0114] Figure 4 Shown are the results of transplanting 4T-1 cells overexpressing human HLA-G into mice to induce tumors, administering anti-HLA-G antibodies, and isolating the tumors to confirm the levels of cytotoxic T cells / regulatory T cells.

[0115] Figure 5 The results of confirming the epitope sequence to which the anti-HLA-G antibody binds to HLA-G are shown. DETAILED DESCRIPTION

[0116] Hereinafter, one or more embodiments are described in more detail by way of examples. However, these examples are provided only for illustrative purposes, and the scope of the present invention is not limited to these examples.

[0117] Example 1: Antigen design

[0118] In order to discover HLA-G specific antibodies and inhibit the mechanism of action of HLA-G, an antigen similar to the structure of b2m-HLA-G multimer was generated, which is the activated form of HLA-G. In order to easily produce the antigen, a protein sequence connected with a signal peptide-b2m-HLA-G-6X His was designed. The DNA sequence ( Figure 1 ). Subsequently, the DNA sequence is introduced into animal cells, and the protein is expressed and purified. Specifically, a nickel-nitrilotriacetic acid (NI-NTA) column is used to perform primary purification of a cell culture fluid containing a signal peptide-b2m-HLA-G-6X His antigen. Then, size exclusion chromatography is used to separate monomers and dimers from the resulting product of primary purification. Antigen production is not limited to the above-mentioned animal cells, and expression and purification can also be performed in, for example, Escherichia coli.

[0119] SEQ ID NO:33: Antigen sequence

[0120] MSRSVALAVLALLSLSGLEARIIPRHLQLGCGGSGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFT PTEKDEYACRVNHVTLSQPKIVKWDRDMGGGGSGGGGSGGGGSGGGGSGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNT KAHAQTDRMNLQTLRGCYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRA DPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWGSGLNDIFEAQKIEWHEHHHHHH

[0121] Example 2: Antibody Generation

[0122] 2-1. Library screening

[0123] The screening of phage / scFv library was performed using an immunotube (15501, Piece) coated with HLA-G antigen. Four pannings were performed to increase the antigen binding specificity of the phage / scFv library. For the recovery and amplification of the selected phage, the exponentially growing Escherichia coli culture was infected with the phage suspension eluted after each round of panning. After the panning was completed, the HLA-G antigen was used to perform pep-phage-enzyme-linked immunosorbent assay (ELISA) to assess the antigenic reactivity of the selected phage. After the fourth round of panning, the antigenic reaction signal of the phage increased to a maximum of 3 times of the background. According to the phage display technology, the increase in signal as described above indicates that the selected phage is rich in HLA-G antigen-specific conjugates. After the fourth round of panning, the phagemid DNA of the selected phage was extracted from the library. 96 clones were isolated and cultured on 24-well plates. The supernatant containing phage particles was tested by phage-ELISA, and the DNA of the clones showing HLA-G specific binding was isolated and sequenced.

[0124] 2-2. Antibody maturation

[0125] For the maturation of HLA-G specific antibodies, mutations were introduced into CDR1, CDR2 and CDR3 of the heavy and light chains to obtain various heavy and light chain products. The products were combined and HLA-G specific antibodies were selected by ELISA analysis using HLA-A, HLA-B, HLA-C, HLA-G to obtain HLA-G specific mature antibodies.

[0126] 2-3. Recombinant production of antibodies

[0127] In this embodiment, use Figure 2 The vector structure of the present invention produces antibodies. The vector includes a human CMV promoter for expression in animal cells, a Kozak sequence for expression enhancement, a signal sequence for extracellular transport of the expressed protein, a variable region cloning site, an IgG1 light chain or heavy chain constant region coding sequence, a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), an ampicillin resistance gene, and pUC for amplifying plasmids in Escherichia coli. Since the variable region cloning site has HindIII and EcoR1 restriction enzyme sites, the expression vector is treated with restriction enzymes, and then the polymerase chain reaction (PCR) product of the heavy chain or light chain variable region is inserted into the vector using an infusion enzyme (TAKARA). The heavy chain constant domains of IgG2, IgG3, and IgG4 can also be used.

[0128] The light chain expression vector and the heavy chain expression vector were transduced into Expi 293 cells using a transduction kit (Thermo), and the cells were then cultured. The cell culture was harvested four to six days later, the cells were removed, and only the supernatant was collected. The collected supernatant was filtered through a 0.45 μm filter and The filtered culture fluid was purified using a Mabselect (Cytiva) purification column in a purification device to obtain an antibody that specifically binds to human HLA-G.

[0129] 2-4. Antibody analysis

[0130] The obtained antibodies were analyzed, and the CDR and variable region sequences are summarized in Tables 1 and 2 below.

[0131] [Table 1]

[0132]

[0133] [Table 2]

[0134]

[0135]

[0136]

[0137]

[0138] Example 3: Evaluation of Antibody Antigen Binding Ability

[0139] The anti-HLA-G specific antibodies obtained in Example 2 were screened for their binding properties to the HLA-G antigen produced in Example 1. The analysis results are summarized in Table 3 below.

[0140] [Table 3]

[0141]

[0142] By surface plasmon resonance (SPR) and octet analysis, it was confirmed that the anti-HLA-G specific antibodies had high affinity for the antigen, as they exhibited nanomolar KD values ​​for HLA-G multimers. In addition, the anti-HLA-G specific antibodies obtained from HLA-G multimers exhibited higher affinity for multimers than for monomers.

[0143] Example 4: Confirmation of the binding inhibition ability of HLA-G specific antibodies

[0144] Since anti-HLA-G specific antibodies have high affinity for HLA-G multimers, it was examined whether these antibodies can inhibit the binding between Ig-like transcript 2 (ILT2) and HLA-G multimers.

[0145] 4-1. Receptor binding inhibition 1: Inhibition of ILT2 binding to HLA-G by anti-HLA-G antibodies

[0146] a. ILT2 blocking ELISA

[0147] For analysis, ILT-2-Fc was diluted to a concentration of 1.5 μg / mL in 1x Dulbecco's phosphate buffered saline (DPBS). The diluted ILT-2 protein was dispensed into each well of a 96-well immunoplate at 150 ng / 100 μL. The immunoplate was stored overnight at 4 ° C to fix the ILT-2 protein to the surface of the well. The next day, the ILT-2 protein solution was completely removed, and each well was washed with 200 μL of 1x phosphate buffered saline (PBS-T) containing Tween. After 200 μL of blocking solution was dispensed into each well, the reactants were reacted at 37 ° C for one hour to block nonspecific protein binding.

[0148] The antigen produced in Example 1 was diluted to 1,200 nM, which is twice the concentration to be treated, with a blocking solution. In addition, the anti-HLA-G single antibody was diluted to 2,000 nM, which is twice the concentration to be treated, with a blocking solution, and then serially diluted three-fold to 0.914 nM.

[0149] The prepared antigen of Example 1 was mixed with anti-HLA-G single antibodies diluted to different concentrations at a ratio of 1:1, and 120 μl of the resulting mixture was dispensed into each well and pre-incubated for 30 minutes at 37° C. After the blocking solution was completely removed from each well, the wells were washed with PBS-T.

[0150] A 1:1 mixture of the antigen of Example 1 and the anti-HLA-G single antibody was added to each well in an amount of 100 μl and allowed to react for one hour at 37° C. Anti-His horseradish peroxidase (HRP) as a detection antibody for the antigen of Example 1 was diluted at a ratio of 1:10,000, dispensed to each well in an amount of 100 μl, and the resulting mixture was allowed to react for one hour at 37° C. Each well was washed three times with 200 μl of 1x PBS-T, and the absorbance was measured at 450 nm using a multi-mode microplate reader.

[0151] The measurement results are shown in Table 4. Table 4 below shows the results of ELISA analysis to confirm the antibody concentration that inhibits 50% or more of the HLA-G:ILT2 interaction when the unblocked HLA-G:ILT2 interaction is treated with different concentrations of the antibody. It was found that the antibody obtained in Example 2 inhibited 50% or more of the HLA-G:ILT2 binding at the 150 nM level.

[0152] [Table 4]

[0153]

[0154] b. ILT-2 blocking cells

[0155] Cells expressing HLA-G were seeded in 96-well microplates at a density of 3.0.E+05 cells / well on day 0 (D0) of the experiment and cultured. The cell supernatant was removed on day 1 of the experiment. Anti-HLA-G single antibody was diluted to 200nM with blocking solution, which is twice the concentration to be treated, and was continuously diluted 6 times to 0.714pM. The diluted solution was distributed to the wells from which the supernatant had been removed and allowed to react for 30 minutes. The ILT2-mFc protein was diluted to 100μg / mL, and the diluted solution was distributed to the antibody-cell reaction solution and allowed to react for one hour. After the reaction was completed, the supernatant was removed, and anti-mouse IgG-fluorescein-5-isothiocyanate (FITC) capable of detecting ILT2-mFc was diluted and distributed. After two hours of reaction, the residual amount of ILT2-mFc was confirmed using a flow cytometer.

[0156] According to the confirmation results, the negative control group, i.e., the IgG1-treated group, did not inhibit the binding of HLA-G and ILT2 even at high concentrations, but the antibody obtained in Example 2 inhibited the binding of HLA-G and ILT2 in a concentration-dependent manner. In addition, the antibody concentration (EC50) at which the HLA-G-expressing cell:ILT2 binding was 50% or less was confirmed, and it was found that the obtained antibody effectively inhibited the binding of IHLA-G and LT2 on the cell surface at the nanomolar level (Table 4).

[0157] 4-2. Receptor binding inhibition 2: Inhibition of the binding of CD8a to HLA-G by anti-HLA-G antibodies

[0158] When the HLA-G antigen binds to CD8a expressed in immune cells, inhibition of immune cells is exhibited, and thus inhibition of the binding of HLA-G and CD8a is important for the activation of immune cells. Therefore, the CD8a blocking effect of the antibody obtained in Example 2 was confirmed as follows.

[0159] The dimer antigen produced in Example 1 was diluted in a PBS solution to a concentration of 5 μg / mL. The diluted antigen was dispensed into each well of a 96-well microplate in an amount of 100 μl per well to coat the wells with the antigen for 24 hours.

[0160] Blocking solution was dispensed into each well of a streptavidin 96-well plate at 100 μl per well for blocking. Blocking solution was prepared by dissolving skim milk at a concentration of 4% in PBS containing 1% Tween-20. Each well of the streptavidin 96-well plate was washed three times with 100 μl of PBS containing 0.1% Tween-20.

[0161] Then, the anti-HLA-G antibody was diluted to a final concentration of 0.391nM with a blocking solution. The diluted anti-HLA-G antibody was distributed to 96 wells and allowed to react for one hour. The CD8a-His diluted with a blocking solution at a concentration of 100nM was distributed to each well and allowed to react for one hour. After the reaction was completed, each well was washed with PBS-T. The anti-CD8a-HRP as a CD8a detection antibody was diluted with a blocking solution and distributed to each well. After one hour of reaction, each well was washed with PBS-T, and tetramethylbenzidine (TMB) solution was added to each well to develop color. The reaction was terminated by adding 1N sulfuric acid, and the absorbance was measured at 450nM using a microplate reader.

[0162] According to the measurement results, it can be seen that the antibody of the present invention blocks the binding of HLA-G and CD8a at a level similar to or higher than that of conventional HLA-G (Table 4). These results indicate that anti-HLA-G antibodies can activate immune cells by inhibiting the binding of HLA-G and CD8a.

[0163] Example 5: Confirmation of cancer cell death using PBMC

[0164] SK-OV-3 cells or MDA-MB-231 cells (target cells) overexpressing HLA-G were cultured in a 37°C incubator for 24 hours. After culture, cells overexpressing HLA-G (target cells) were pretreated with anti-HLA-G antibodies at a concentration of 100 nM for one hour at 37°C. PBMCs (effector cells) and antibody-treated target cells were mixed at a ratio of 5:1 and co-cultured with SK-OV-3 cells or MDA-MB-231 cells for 48 hours.

[0165] After the culture is completed, the cell culture fluid is recovered. According to the manufacturer's protocol, the lactate dehydrogenase (LDH) level in the recovered cell culture fluid is measured using a cytotoxicity assay kit (cytotox96 non-radioactive cytotoxicity assay, Promega). Since LDH is released when cells die, the extent of cell death can be determined by measuring LDH levels.

[0166] According to the measurement results, it was confirmed that anti-HLA-G antibody 2, antibody 1, and antibody 3 enhanced the cancer cell killing ability of PBMC compared with the negative control group (IgG1 pretreatment) that does not specifically bind to HLA-G ( Figure 3 ).

[0167] Example 6: Confirmation of the tumor growth inhibitory effect of HLA-G antibody

[0168] 4T-1 cells overexpressing human HLA-G were transplanted into the right abdominal cavity of BALB / c mice. Tumor growth was observed 7 to 14 days after transplantation, and mice were raised until the tumor size grew to a certain level (100 mm 3 ) or larger. When the tumor size reached the expected size, the tumor-transplanted mice were randomly divided into test groups according to Table 5.

[0169] [Table 5]

[0170] Test Group Administered substances Dose (mpk) Group 1 IgG1 10 Group 2 Anti-HLA-G Antibody 4 1 Group 3 Anti-HLA-G Antibody 4 10 Group 4 Anti-HLA-G Antibody 1 1 Group 5 Anti-HLA-G Antibody 1 10 Group 6 Anti-HLA-G Antibody 2 1 Group 7 Anti-HLA-G Antibody 2 10 Group 8 Anti-HLA-G Antibody 3 1 Group 9 Anti-HLA-G Antibody 3 10

[0171] The anti-HLA-G antibody was intraperitoneally administered to each test group at a dose of 1 mg / kg (mg / kg=mpk) or 10 mg / kg, twice a week (BIW), for a total of four times in two weeks. On the 12th day after the start of the experiment, the volume of visible tumors under the skin of the mice was measured, and the tumor growth inhibition rate was calculated according to the following equation 1.

[0172] [Equation 1]

[0173] Tumor growth inhibition (TGI) rate (%) = (tumor volume of negative control group (IgG) - tumor volume of test group) / tumor volume of negative control group

[0174] The results of the tumor growth inhibition rate calculation are shown in Table 6 below.

[0175] [Table 6]

[0176]

[0177]

[0178] The negative control group, i.e., the IgG1 administration group, did not inhibit tumor growth, while all anti-HLA-G antibody treatment groups inhibited tumor growth. Antibody 4 showed 24.9% tumor growth inhibition when administered at a dose of 10 mpk, and antibodies 1, 2, and 3 showed more than 20% tumor growth inhibition even when administered at a dose of 1 mpk (Table 6).

[0179] In addition, tumor tissues were isolated from mice treated with anti-HLA-G antibodies, and immune cells infiltrating the tumors were analyzed. The effect of immunotherapy changes the immune cell pool in tumor tissues, and cancer cells are killed due to the activation of immune cells. Cytotoxic T cells are representative immune cells with cancer cell killing function, and regulatory T (Treg) cells are representative immunosuppressive factors.

[0180] As a result of confirming the levels of cytotoxic T cells / regulatory T cells in tumor tissues, it can be seen that the levels of cytotoxic T cells / regulatory T cells were higher in all experimental groups to which anti-HLA-G antibodies were administered compared to the negative control group (mock) ( Figure 5 ). These results imply that anti-HLA-G antibodies increase the function of cytotoxic T cells.

[0181] Example 7: Confirmation of the binding site between antibody and HLA-G

[0182] Through preliminary experiments, it was confirmed that when the quenching buffer was used for the antigen and the pepsin solution (1:1 w / w) was treated at low temperature for five minutes, the highest overall sequence coverage of 95.5% was achieved. Therefore, epitope mapping experiments were performed under these conditions. The quenching buffer contained 100 mM potassium phosphate, 1 M urea, and 500 mM tris (2-carboxyethyl) phosphine hydrochloride (TCEP) (pH 2.5).

[0183] Epitope mapping was performed using hydrogen deuterium exchange mass spectrometry (HDX-MS) technique, β2M-HLA-G was used as an antigen and anti-HLA-G antibody 1 or 2 was used as an antibody.

[0184] The samples in the state of antigen alone and antigen-antibody complex were each labeled with D2O buffer (using triplicate samples). Thereafter, mass spectrometry was performed at five time points: 0 min, 0.33 min (20 sec), 10 min, 60 min, and 240 min, and the molecular weight values ​​obtained by the spectra were compared to determine the fraction of deuterium absorption reduction of the complex compared to the antigen alone.

[0185] As a result, it was confirmed that when the antigen binds to each of the two types of antibodies, the sequences of amino acids 339 to 344 (DYEATL) and amino acids 390 to 402 (VVVPSGEEQRYTC) of the antigen serve as the same epitope. In addition, for antibody 1, it can be seen that the amino acid 323 to 338 (QRADPPKTHVTHHPVF) portion is also an epitope adjacent to amino acids 339 to 344 ( Figure 5 ).

Claims

1. An anti-human leukocyte antigen-G (HLA-G) antibody or an antigen-binding fragment thereof, comprising: (a) a heavy chain complementary determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:5, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:6, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:7; (b) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15; (c) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 19; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 22, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 23; or (d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and A light chain CDR1 comprising the amino acid sequence of SEQ ID NO:29, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:

31.

2. The anti-HLA-G antibody or antigen-binding fragment thereof according to claim 1, wherein the HLA-G specific antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 4; and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 8; (b) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 12; and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 16; (c) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 20; and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 24; or (d) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 28; and a light chain variable region consisting of the amino acid sequence of SEQ ID NO:

32.

3. The anti-HLA-G antibody or antigen-binding fragment thereof according to claim 1, wherein the anti-HLA-G antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, a mixture of monoclonal and / or polyclonal antibodies, a human antibody, a humanized antibody or a chimeric antibody.

4. The anti-HLA-G antibody or antigen-binding fragment thereof of claim 1, wherein the antigen-binding fragment is selected from the group consisting of an antigen-binding fragment (Fab), Fab', F(ab')2, a variable fragment (Fv), a disulfide-stabilized Fv fragment (dsFv), a single-chain Fv (scFv), a diabody, a triabody, and a tetrabody.

5. An isolated nucleic acid comprising a nucleotide sequence encoding the anti-HLA-G antibody or antigen-binding fragment thereof according to claim 1.

6. A vector comprising the isolated nucleic acid according to claim 5. A host cell comprising the vector according to claim 6 .

8. A pharmaceutical composition for preventing or treating cancer, comprising one or more active ingredients selected from the group consisting of: (a) the anti-HLA-G binding antibody or antigen-binding fragment thereof according to claim 1; (b) the isolated nucleic acid of claim 5; (c) the vector according to claim 6; or (d) the host cell according to claim 7; and A pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, wherein the cancer is selected from the group consisting of pancreatic cancer, breast cancer, ovarian cancer, glioma, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, liver cancer, lung cancer, colon cancer, nasopharyngeal cancer, oral cancer, thyroid cancer, prostate cancer, kidney cancer, gallbladder cancer, bile duct cancer, blood cancer and melanoma. 10 . A method for preventing or treating cancer, comprising administering the anti-HLA-G binding antibody or antigen-binding fragment thereof according to claim 1 or the pharmaceutical composition according to claim 8 to a subject in need thereof.

11. An HLA-G epitope consisting of a sequence selected from the group consisting of SEQ ID NOs: 34 to 36.

12. An antibody that binds to an HLA-G epitope consisting of a sequence selected from the group consisting of SEQ ID NOs: 34 to 36.

Citation Information

Patent Citations

  • Process for the purification of recombinant polypeptides

    WO1988007085A1

  • Leader sequences for the production of recombinant proteins

    WO1988007086A1

  • Targeted multifunctional proteins

    WO1988009344A1